Dipeptidyl-Peptidase IV Inhibitors — Competitive Intelligence Brief

Dipeptidyl-Peptidase IV Inhibitors (Dipeptidyl-Peptidase IV Inhibitors) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor. Area: Diabetes.

phase 3 DPP-4 inhibitor Dipeptidyl peptidase IV (DPP-4) Diabetes Small molecule

Target snapshot

Dipeptidyl-Peptidase IV Inhibitors (Dipeptidyl-Peptidase IV Inhibitors) — National University of Malaysia. Dipeptidyl-peptidase IV (DPP-4) inhibitors block the enzyme that degrades incretin hormones, thereby increasing insulin secretion and reducing glucagon in response to meals.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dipeptidyl-Peptidase IV Inhibitors TARGET	Dipeptidyl-Peptidase IV Inhibitors	National University of Malaysia	phase 3	DPP-4 inhibitor	Dipeptidyl peptidase IV (DPP-4)
Janumet, Lantus	Janumet, Lantus	Chinese University of Hong Kong	marketed	DPP-4 inhibitor + biguanide (Janumet); long-acting basal insulin (Lantus)	DPP-4 enzyme, metformin (AMPK pathway), insulin receptor (Lantus)
Sitagliptin (Januvia)	Sitagliptin (Januvia)	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	marketed	DPP-4 inhibitor	DPP-4 (dipeptidyl peptidase-4)
Metformin and Saxagliptin	Metformin and Saxagliptin	ikfe-CRO GmbH	marketed	Biguanide + DPP-4 inhibitor combination	Metformin: mitochondrial glycerophosphate dehydrogenase; Saxagliptin: DPP-4 (dipeptidyl peptidase-4)
CSII followed by Lina+MET	CSII followed by Lina+MET	Sun Yat-sen University	marketed	Insulin therapy combined with DPP-4 inhibitor and biguanide	Insulin receptor (CSII); DPP-4 enzyme (linagliptin); mitochondrial glycerophosphate dehydrogenase (metformin)
Sitagliptin combined with metformin	Sitagliptin combined with metformin	Sun Yat-sen University	marketed	DPP-4 inhibitor combined with biguanide	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I
Sitagliptin + Metformin	Sitagliptin + Metformin	Baylor College of Medicine	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor class)

1. Merck Sharp & Dohme LLC · 5 drugs in this class
2. Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class
3. AstraZeneca · 4 drugs in this class
4. LG Life Sciences · 2 drugs in this class
5. Tanabe Pharma Corporation · 2 drugs in this class
6. Ain Shams University · 2 drugs in this class
7. Ono Pharmaceutical Co. Ltd · 2 drugs in this class
8. Cinnagen · 1 drug in this class
9. GRADE Study Group · 1 drug in this class
10. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class